Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Accelrys
Catalyst 4.8 released for lead identification, optimization
July 30th, 2003
Accelrys, a wholly owned subsidiary of Pharmacopeia, Inc., (PCOP) announced the release of Catalyst 4.8, the latest version of its rational drug design application for lead identification and optimization. Catalyst now includes HypoRefine, a new algorithm that yields more accurate predictive models, improving the quality of computer aided drug design. Other enhancements yield better identification and optimization of lead-like candidates through scientific advances that enable discovery of better molecular conformations, allow greater coverage of pharmacophore space in calculations, ensure better predictions using Quantitative Structure Activity Relationship (QSAR)...
Source: Biotech Week (2003-07-30)
|
